/stocks — the workspaceLOADING
All QNRX SEC filings, by type → · Earnings date & implied move · Search inside filings
QNRX is not among the 142 companies we ingest every day, so it is not in the fundamentals screener or the size and group lists built from it. This page reads its SEC filings when the page is built. Ask us to add it: we keep a count per ticker and nothing about you.
Latest report (10-Q, filed 2026-08-14). Three months to 2026-06-30 against 2025-06-30: Net loss $5.4M, 45.3% larger than $3.7M. Six months to 2026-06-30 against 2025-06-30: Operating cash used $8.0M, 27.6% larger than $6.3M. Read it line by line, each linked to its source → · Every report →
Quoin Pharmaceuticals Ltd. (QNRX) is a pharmaceutical preparations company. Piotroski F-Score 1/6. 6 insider Form 4 filings in the last 90 days. Next earnings projected around 2026-11-05 from QNRX's year-over-year reporting pattern (not yet company-confirmed). Fundamentals from SEC filings; prices are end-of-day.
Every filed figure on this page is free to read, dated and sourced; no column is held back for a paid plan. Each section with figures says what date they are true as of and where they come from.
What’s behind QNRX’s latest move — the size, how unusual the volume is, and the catalyst on the tape, explained and cited to the source.
End-of-day bars · delayed, not real-time · data: Databento · studies computed in your browser from these barsCharting by TradingView Lightweight Charts™
EPS and P/E withheld: the newest dollar EPS it has tagged is for the period ending 2021-12-31.
XBRL company facts, SEC EDGAR. TTM = last four reported quarters. Valuation ratios arrive with a price source — we don't fake quotes.
Not reported in XBRL for this filer.
Not reported in XBRL for this filer.
↓ Download the fiscal-year statement table: XLSX · CSV · revenue, income, EPS, cash flow, balance sheet · from SEC XBRL, dated
As filed. We do not recategorize line items. Each chart plots one XBRL concept exactly as QNRX tagged it: net income us-gaap:NetIncomeLoss, period by period; a period the company did not tag on its own is left out, not estimated. A figure that disagrees with the filing is a bug in our extraction, not a policy, and we fix it: report a mismatch.
A plain-English read on QNRX plus an auto-SWOT, built from QNRX's SEC filings and market data, every point cited, nothing invented. Educational, not investment advice.
Four AI analysts, a bull, a bear, a risk manager, and a PM, debate QNRX using only the SEC-filing and market facts below. Every point cites its evidence; nothing is invented. This is educational research, not investment advice.
Ask about QNRX’s revenue, earnings, valuation, filings, insiders or Congress trades. Answers come only from the numbered evidence the research brief uses, each citing the items it rests on. A question about one figure is answered by code, free. One that puts figures together is 1 generation (Pro). A question about whether to buy, sell or hold, how much, or where the price goes gets a refusal.
Educational only — not financial advice. Data from SEC EDGAR public filings; no live market data is shown. Figures reflect the company's own reported XBRL facts and may lag.
Has QNRX been issuing shares? Offering history →
On file for QNRX from Nov 4, 2026 to Nov 17, 2026: earnings date (below).
| Event | Result |
|---|---|
| Earnings date | on file. QNRX reports: Nov 5 (projected from past report dates, not company-confirmed; window Oct 31 to Nov 10; usually after the close, from past SEC filing times). source |
| Filing deadline | nothing in the window. No deadline computed: the submissions file states no fiscal year end, so the next report cannot be told apart as a 10-K or a 10-Q. filing list on EDGAR |
| Ex-dividend date | not covered. Not checked. This attestation does not cover ex-dividend dates. |
This records what these sources returned when they were read. It is not a forecast: a company can announce an event at any time, and ex-dividend dates are not covered. Window 2026-11-04 to 2026-11-17, Eastern dates. Deadlines follow SEC Rules 13a-1 and 13a-13 and Form 20-F, moved past weekends and federal holidays by Rule 0-3.
Volume against its own history: 36% of its last 252 sessions were lighter than the last one, the 2026-11-03 session. End-of-day bars (Databento). Volume detail
Closes only, split-adjusted. An average needs that many sessions on file to print. These are measurements, not support, resistance or targets. Chart with studies
Projected from QNRX's own SEC 8-K filing history — the year-over-year reporting pattern (about 47% land the exact day, about 91% within a week, measured across 4,713 past reports). No analyst estimates and nothing invented, and every confirmed date links to the source it came from, so you can check it yourself. It upgrades the momentQNRX files or announces.
QNRX has sold off after 6 of its last 8 earnings reports.
Each figure is one earnings reaction — how much QNRX moved from the closing price the day before a report to the close the day after. Based on its last 8 reports.
Large earnings reactions have been common.
QNRX has traded lower after most recent earnings releases.
The average is inflated by its most volatile prints (+21.1% and -30.9%).
A more typical earnings reaction has been approximately ±7.7%.
Realized close-to-close history only — no options-implied move, no analyst estimates.
| Reported | Close-to-close |
|---|---|
| 2026-08-14 | -14.2% |
| 2026-05-07 | -7.8% |
| 2026-03-26 | -30.9% |
| 2025-11-06 | -6.6% |
| 2025-08-07 | -3.0% |
| 2025-05-14 | +21.1% |
| 2025-03-13 |
Earnings dates are the company's 8-K Item 2.02 filings (SEC). Reactions from Databento EOD.
| +2.5% |
| 2024-11-08 | -7.6% |
Group: Pharmaceutical Preparations, the SEC industry code QNRX files under. 10 companies in our stored table file under it.
| Metric | QNRX | Group median | 25th to 75th percentile | Where QNRX sits |
|---|---|---|---|---|
| Net marginnet income divided by revenue, same fiscal year | not placed | 21.4%⊙INFERENCE — derived by arithmetic SourceNet margin across the 10 companies filing under SEC SIC "Pharmaceutical Preparations" in our stored table As offiscal years ended 2025-12-28 to 2025-12-31 HowEach company's net income divided by revenue, same fiscal year, from its newest annual report as stored. The median is the middle value; the 25th to 75th percentile is the middle half, linear between ranks. A group prints from 6 companies with the figure. | 13.0% to 28.4% | QNRX has no annual report in the stored table yet, so it has no figure to place. |
| Free cash flow marginoperating cash flow less capital expenditure, divided by revenue, same fiscal year | not placed | 20.9%⊙INFERENCE — derived by arithmetic SourceFree cash flow margin across the 9 companies filing under SEC SIC "Pharmaceutical Preparations" in our stored table As offiscal years ended 2025-12-28 to 2025-12-31 HowEach company's operating cash flow less capital expenditure, divided by revenue, same fiscal year, from its newest annual report as stored. The median is the middle value; the 25th to 75th percentile is the middle half, linear between ranks. 1 of the 10 companies in the group lack the figure and are not counted. A group prints from 6 companies with the figure. | 16.7% to 26.7% | QNRX has no annual report in the stored table yet, so it has no figure to place. |
| Return on equitynet income divided by stockholders’ equity at the fiscal year end | not placed | 32.9%⊙INFERENCE — derived by arithmetic SourceReturn on equity across the 9 companies filing under SEC SIC "Pharmaceutical Preparations" in our stored table As offiscal years ended 2025-12-28 to 2025-12-31 HowEach company's net income divided by stockholders’ equity at the fiscal year end, from its newest annual report as stored. The median is the middle value; the 25th to 75th percentile is the middle half, linear between ranks. 1 of the 10 companies in the group lack the figure and are not counted. A group prints from 6 companies with the figure. | 12.5% to 38.2% | QNRX has no annual report in the stored table yet, so it has no figure to place. |
One filed metric per row, each a ratio of two figures from the same annual report; no composite and no grade. Percentile is the share of the group’s other companies with a lower figure. A group prints from 6 companies with the figure. The group is drawn from our stored table (the S&P 500 issuers and the companies we cover, each with its newest annual report read), not from every filer in the class. Industry pages show the same medians by group.
Daily closes from 2024-07-01 through 2026-11-03, 588 sessions, split-adjusted (2 splits applied). No direction, pattern, entry, target or overbought label: these are measurements. Filings dated on the move days are in QNRX’s filings; the chart with studies draws every figure.
Written by code from 588 end-of-day bars through 2026-11-03. Written by code from the data on file, not by a model. Information, not investment advice: it describes the security and recommends nothing to anyone.
None of the 5 estimators could run on QNRX's filings.
One estimator is a point estimate, not a range, so no band and no valuation label are published for QNRX. Below is everything that was checked, so the refusal can be read rather than taken on trust.
Nothing produced a value.
No fiscal year of price history was on record; the historical multiples need 5. No sector peer set is priced for QNRX, so sector medians could not fill the gaps.
Every refusal recorded for QNRX → · How often we decline, and why →
No tracked institution reported a position in QNRX in the latest 13F round.
No lawmaker has disclosed a trade in QNRX under the STOCK Act.
| Carter Denise P.Chief Operating Officer | BUY | $100K | view → |
| Myers MichaelChief Executive Officer | BUY | $100K | view → |
| Lawlor Sally BridgetChief Financial Officer | BUY | $50K | view → |
| Culverwell Anthony JamesDirector | BUY | $30K | view → |
2 of the 2 checks that ran found nothing new for QNRX. 2 could not run.
Each event check looks back 30 days from the date its own source was stored, read or generated, never from the date this page was built. A check that finds nothing is a measurement of that window, not a forecast, and a check that cannot be dated does not make the claim at all.
From SEC Form 4 and 13F filings. Both are backward-looking disclosures on different reporting clocks, and neither predicts price. Educational information only — not investment advice.
Head office: Ashburn, Virginia, United States · the company’s charter and its head office are in different countries.
Source: the cover page of Quoin Pharmaceuticals Ltd.’s 10-Q filed 2026-08-14, on EDGAR. Filings checked 2026-11-04. Incorporation is where the company’s charter was filed. It is not where the business operates or earns, which no filing cover states. How this works